In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...
In this video, Stephen M. Ansell, MD, PhD professor of medicine, chair of the division of hematology, co-leader of the hematological malignancies program, and interim chair of the department of ...
During a Case-Based Roundtable® event, Natalie Galanina, MD, discussed data from the ZUMA-7 and TRANSFORM trials in the first ...
Panelists discuss exciting updates on Bruton tyrosine kinase (BTK) inhibitors from the 2024 American Society of Hematology ...
Hosted on MSN1h
NICE green lights two blood cancer therapies for NHS useBMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.
GlobalData on MSN9h
Sellas reports Phase IIa trial data of SLS009 for DLBCL treatmentSellas Life Sciences has reported the multicentre Phase IIa trial data of a highly selective cyclin-dependent kinase 9 (CDK9) ...
Researchers have discovered and analyzed a rare but serious side effect of an innovative form of blood cancer therapy. The ...
The descriptive term AtLP may be used as an interim label when morphologic and molecular features are not sufficient to render a positive diagnosis of lymphoma ... multiclonal B cells, T cells ...
Doctors are hoping a clinical trial at Harris Health Ben Taub will prove the treatment works and it’s worth getting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback